Stockscreener 앱 받기
11.66
0.09%
0.010
시간 외 거래:
11.65
-0.010
-0.09%
Viatris Inc 주식(VTRS)의 최신 뉴스
Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., - pharmiweb.com
Is Viatris Stock Outperforming the Dow? - Barchart.com
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back - The Globe and Mail
Risk Analysis: How Viatris Inc VIA stock behaves in tightening cyclesJuly 2025 Snapshot & Verified Swing Trading Watchlist - moha.gov.vn
Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare
Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq
Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com
Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN
Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com
CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks
Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView — Track All Markets
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com
Viatris signs agreements with Biocon on $815m stake sale - Yahoo Finance
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha
Viatris sells Biocon Biologics stake for $815 million - MSN
Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan
Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - Yahoo Finance
Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine
Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com - Investing.com Nigeria
Viatris Holds Annual Shareholder Meeting on December 5 - TipRanks
Viatris shareholders elect directors and approve proposals at annual meeting - Investing.com India
Mark Cuban Takes Aim at FDA Fees - GuruFocus
Why Viatris Inc. (VIA) stock trades below fair valueJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing - Seeking Alpha
Can Viatris Inc. (VIA) stock survive global slowdownWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
Can Viatris Inc. (VIA) stock surprise markets with earningsTrade Volume Summary & Low Drawdown Momentum Ideas - Newser
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Weekly Stock Analysis & AI Based Buy/Sell Signal Reports - Newser
Why Viatris Inc. (VIA) stock is a must watch tickerJuly 2025 Patterns & Risk Controlled Daily Plans - Newser
Is Viatris Inc. (VIA) stock a good hedge against inflationMarket Growth Summary & Stock Portfolio Risk Management - Newser
How Viatris Inc. stock benefits from global expansion2025 Top Gainers & High Conviction Investment Ideas - Newser
Will Viatris Inc. (VIA) stock extend growth storyMarket Risk Summary & Risk Managed Investment Strategies - Newser
How Viatris Inc. (VIA) stock compares with market leadersWeekly Stock Report & Step-by-Step Swing Trade Plans - Newser
Viatris Inc.: Revenue and Earnings Analysts Forecasts Revisions | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Target Price Consensus and Analysts Recommendations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Financial Data Forecasts Estimates and Expectations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Dividend historical data and projections - marketscreener.com
What market sentiment indicators show for Viatris Inc. (VIA) stockJuly 2025 Big Picture & Technical Buy Zone Confirmations - Newser
Behavioral Patterns of VTRS and Institutional Flows - news.stocktradersdaily.com
Levi & Korsinsky Notifies Viatris Inc. (VTRS) Shareholders of Class Action Lawsuit and June 3, 2025 Deadline - The National Law Review
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
How Viatris Inc. (VIA) stock trades after earningsMarket Rally & Risk Controlled Stock Pick Alerts - moha.gov.vn
Non-operating income (total) of Viatris, Inc. – SIX:VTRS - TradingView
Viatris Inc. (VIA.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Shareholders That Lost Money on Viatris Inc. (VTRS) Should Contac - The National Law Review
These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday - Benzinga
Merz Loses Bid To Block Viatris In Unified Patent Court - Law360
What Do Recent Portfolio Streamlining Moves Mean for Viatris’s True Value in 2025? - Yahoo Finance
0.50%
자본화:
|
볼륨(24시간):